A biotechnology company focused on therapies that address blood clotting disorders and complications from anticoagulant drugs. Its portfolio included Andexxa, an FDA‑approved reversal agent for certain factor Xa inhibitors, and Bevyxxa, an anticoagulant designed to prevent venous thromboembolism in ...
1 member of Congress has disclosed 1 trade in Portola Pharmaceuticals, Inc. (PTLA), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-06-10 | MICHAEL T. MCCAUL | sell | $1K – $15K |